Joseph Oliveto
Chief Executive Officer bij MILESTONE PHARMACEUTICALS INC.
Vermogen: 509 504 $ op 31-03-2024
Profiel
Joseph G.
Oliveto is currently the President, Chief Executive Officer & Director at Milestone Pharmaceuticals, Inc. and the President & Chief Executive Officer at Milestone Pharmaceuticals USA, Inc. He previously held positions as the President, Chief Executive Officer & Director at Chelsea Therapeutics International Ltd., the Chief Executive Officer & Director at Galleon Pharmaceuticals, Inc., the Director-Global Alliance at Hoffmann-La Roche, Inc., and the Executive-in-Residence at Pappas Capital LLC.
Mr. Oliveto obtained his undergraduate degree and MBA from Rutgers State University of New Jersey.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2023 | 284 639 ( 0.54% ) | 509 504 $ | 31-03-2024 |
Actieve functies van Joseph Oliveto
| Bedrijven | Functie | Begin |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Chief Executive Officer | 07-03-2017 |
Milestone Pharmaceuticals USA, Inc.
 Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Milestone Pharmaceuticals, Inc., Milestone Pharmaceuticals USA, Inc. develops cardiovascular drugs. The private company is based in Charlotte, NC. Joseph G. Oliveto has been the CEO of the company since 2017. | Chief Executive Officer | 07-03-2017 |
Eerdere bekende functies van Joseph Oliveto
| Bedrijven | Functie | Einde |
|---|---|---|
Galleon Pharmaceuticals, Inc.
 Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Chief Executive Officer | 01-06-2016 |
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Chief Executive Officer | 23-06-2014 |
Pappas Capital LLC
 Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Corporate Officer/Principal | 30-06-2008 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01-01-2008 |
Opleiding van Joseph Oliveto
| Rutgers State University of New Jersey | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MILESTONE PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Chelsea Therapeutics International Ltd.
 Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Part of Milestone Pharmaceuticals, Inc., Milestone Pharmaceuticals USA, Inc. develops cardiovascular drugs. The private company is based in Charlotte, NC. Joseph G. Oliveto has been the CEO of the company since 2017. | Health Technology |
